NGENF 2.00 NervGen Pharma Corp.
| Range: | 1.16-2.99 | Vol Avg: | 38093 | Last Div: | 0 | Changes: | 0.02 |
| Beta: | 1.33 | Cap: | 0.12B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Wed Apr 03 2019 | Empoloyees: | 11 | ||
| CUSIP: | CIK: | ISIN: | CA64082X2032 | Country: | CA | ||
| CEO: | Mr. Michael Kelly | Website: | https://www.nervgen.com | ||||
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow